133 related articles for article (PubMed ID: 14668577)
1. Effect of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities.
Bełtowski J; Wójcicka G; Jamroz A
J Cardiovasc Pharmacol; 2004 Jan; 43(1):121-7. PubMed ID: 14668577
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat.
Bełtowski J; Wójcicka G; Jamroz A
Pol J Pharmacol; 2002; 54(6):661-71. PubMed ID: 12866722
[TBL] [Abstract][Full Text] [Related]
3. The paraoxonase 1 (PON1), platelet-activating factor acetylohydrolase (PAF-AH) and dimethylarginine dimethylaminohydrolase (DDAH) activity in the metformin treated normal and diabetic rats.
Wójcicka G; Jamroz-Wiśniewska A; Czechowska G; Korolczuk A; Marciniak S; Bełtowski J
Eur J Pharmacol; 2016 Oct; 789():187-194. PubMed ID: 27450486
[TBL] [Abstract][Full Text] [Related]
4. The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity.
Wójcicka G; Jamroz-Wiśniewska A; Marciniak A; Łowicka E; Bełtowski J
Life Sci; 2010 Jul; 87(3-4):126-32. PubMed ID: 20638992
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Experientia; 1995 Mar; 51(3):223-6. PubMed ID: 7698284
[TBL] [Abstract][Full Text] [Related]
6. Species differences in the inhibiting effect of fluvastatin, a new inhibitor of HMG-CoA reductase, on cholesterol biosynthesis.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Res Commun Mol Pathol Pharmacol; 1994 Dec; 86(3):325-34. PubMed ID: 7712108
[TBL] [Abstract][Full Text] [Related]
7. Not all statins interfere with clopidogrel during antiplatelet therapy.
Mach F; Senouf D; Fontana P; Boehlen F; Reber G; Daali Y; de Moerloose P; Sigwart U
Eur J Clin Invest; 2005 Aug; 35(8):476-81. PubMed ID: 16101667
[TBL] [Abstract][Full Text] [Related]
8. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes.
Yamamoto A; Hoshi K; Ichihara K
Eur J Pharmacol; 1998 Nov; 361(1):143-9. PubMed ID: 9851551
[TBL] [Abstract][Full Text] [Related]
9. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis.
Liberopoulos EN; Papavasiliou E; Miltiadous GA; Cariolou M; Siamopoulos KC; Tselepis AD; Elisaf MS
Perit Dial Int; 2004; 24(6):580-9. PubMed ID: 15559488
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
Hagiwara M; Kataoka K; Arimochi H; Kuwahara T; Nakayama H; Ohnishi Y
World J Gastroenterol; 2005 Feb; 11(7):1040-3. PubMed ID: 15742411
[TBL] [Abstract][Full Text] [Related]
11. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans.
Nash JD; Burgess DS; Talbert RL
J Med Microbiol; 2002 Feb; 51(2):105-109. PubMed ID: 11863260
[TBL] [Abstract][Full Text] [Related]
12. Direct effects of statins on the vascular wall.
Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy.
Ogata Y; Takahashi M; Takeuchi K; Ueno S; Mano H; Ookawara S; Kobayashi E; Ikeda U; Shimada K
J Cardiovasc Pharmacol; 2002 Dec; 40(6):907-15. PubMed ID: 12451324
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
Variya BC; Patel SS; Trivedi JI; Gandhi HP; Rathod SP
Eur J Pharmacol; 2015 Oct; 764():283-291. PubMed ID: 26169562
[TBL] [Abstract][Full Text] [Related]
15. Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidaemic rabbits.
Suzumura K; Kasahara E; Ohnishi Y; Chien KC; Inoue M
Clin Exp Pharmacol Physiol; 2000 Sep; 27(9):709-14. PubMed ID: 10972538
[TBL] [Abstract][Full Text] [Related]
16. EPR studies on hydroxyl radical-scavenging activities of pravastatin and fluvastatin.
Vandjelovic N; Zhu H; Misra HP; Zimmerman RP; Jia Z; Li Y
Mol Cell Biochem; 2012 May; 364(1-2):71-7. PubMed ID: 22207075
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes.
Takahashi HK; Mori S; Iwagaki H; Yoshino T; Tanaka N; Weitz-Schmidt G; Nishibori M
J Leukoc Biol; 2005 Mar; 77(3):400-7. PubMed ID: 15618295
[TBL] [Abstract][Full Text] [Related]
19. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
Kantola T; Backman JT; Niemi M; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 2000 Jun; 56(3):225-9. PubMed ID: 10952477
[TBL] [Abstract][Full Text] [Related]
20. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia.
Bełtowski J; Wójcicka G; Jamroz A
Atherosclerosis; 2003 Sep; 170(1):21-9. PubMed ID: 12957679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
